Lille

• An Interventional, Phase II, Non Randomized, Mono-centric Study on the Clinical Efficacy and Safety of the Medical Device PAGETEX® as a Phot … Recruiting
  2024-514093-41-00 4 2019-08-27 Vulvar Extra Mammary Paget's Disease confirmed by biopsy
• Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma … Recruiting
  2023-510559-41-00 4 2026-06-15 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
• A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Recruiting
  2024-519246-75-01 4 2026-06-15 Patients With Muscle-Invasive Bladder Cancer
• Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial Recruiting
  2025-524297-42-00 5 2026-06-12 CLTI defined as Rutherford category 4 or 5
• A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc … Recruiting
  2024-519511-33-00 4 2026-06-11 Patients will be included with a stable but active disease (as defined
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Recruiting
  2025-521587-35-00 5 2026-06-03 Metastatic colorectal cancer
• The Efficacy of Pressurised Intraperitoneal aerosol chemotherapy (PIPAC) combined with CURativE intent minimally invasive radical resection … Recruiting
  2024-516194-76-00 4 2026-05-28 Gastric adenocarcinoma
• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe He … Recruiting
  2023-505805-18-00 5 2026-05-27 Hemophilia B
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 5 2026-05-07 Colon carcinoma
• COMMODITIES : Comparison of initial dual oral COMbination therapy to MOnotherapy in pulmonary arterial hypertension with cardiovascular como … Recruiting
  2023-509891-40-00 5 2026-04-28 Pulmonary arterial hypertension
• PIPELINE-RSV-France Recruiting
  2025-521755-23-00 5 2026-04-28 Respiratory syncytial virus infection
• AMAZE 12: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight maintain their weight loss Recruiting
  2025-523804-62-00 5 2026-04-28 Obesity
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting
  2024-519208-29-00 4 2026-04-02 Pleural mesothelioma
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• A study to test whether nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis Recruiting
  2025-522383-33-00 5 2026-03-23 Pulmonary fibrosis
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-522713-29-00 5 2026-03-12 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs Recruiting
  2025-523297-16-00 1 2026-02-27 Non-Hodgkin Lymphoid Malignancies (NHLs)
• Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting
  2025-522015-42-00 10 2026-02-26 Chronic Hepatitis D Infection
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can

Showing 121–144 of 703 trials